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INTRODUCTION
In many developing countries Myocardial infarction has
becoming a major problem in public health 1,2. MI is a multifactorial
disease caused by genetic and environmental factors.The major cause of
death in the world is Myocardial infarction 3. The high plasma lipid
levels, high plasma glucose levels,high blood pressure, obesity, smoking,
and family history of cardiac disease are the most important risk factors
for MI. MI is mainly due to atherosclerosis of the coronary arteries .
The structural changes, which permits the accumulation of cells,
extracellular matrix and lipids in the intimate layer of the diseased artery
and allows the growth of atherosclerotic plaque. The fibrous cap lining
atheromatous plaque gets ruptured, gives rise to thrombosis, and its
complications4.
Pathophysiology of MI involves a wide variety of proteins,
including the matrix metalloproteinases (MMPs).Atheromatous plaque
formation is facilitated by the action of MMPs. Major extra cellular
components of the basal lamina around blood vessels such as type 1V
collagen, laminin, and fibronectin are degraded by MMP-2. MMPs
also weakens the arterial wall, resulting destabilizing of atheromatous
plaque and dissolution of fibrous cap leading to MI5.
Matrix metalloproteinases are zinc dependent endopeptidases
that degrade components of the extracellular matrix (ECM). 72KDa type
IV collagenase also known as MMP-2, is an ubiquitous
metalloproteinase involved in various functions such as vascular
remodeling, atheromatous plaque rupture, and degrading matrix
proteins. MMP-2, also known as gelatinase A . In human, it is
encoded by the MMP-2 gene6.
MMP-2 is produced as zymogen, after the production pro MMP-
2 is thought to be bound to its specific inhibitor, called as tissue
inhibitor of matrix metalloproteinases-2 . There are several pathways for
activation of the proenzyme, but mainly the most important pathway is
activation by membrane type metalloproteinases-1 (MT1-MMP)7. MTI-
MMP binds to TIMP-2,this complexed structure comes near to the
active site of the MT-MMP enzyme. This results to removal of two
specific pro peptides from pro MMP-2 and the production of an
active 72 KDa MMP-2 enzyme8.
The gene for human MMP-2 contains 27,862 basepair genomic
DNA and is composed of 13 exons. It has been localized on chromosome
16q219. Several common restriction fragment length polymorphisms
(RFLPs) have been reported in the MMP-2 gene locus. MMP-2 gene –
1306C>T promoter region is linked with development of MI10. This
base transition is situated in CCACC box of the sp1 binding site.
 Increased MMP-2 levels have been found in the plasma of
patients with MI11. Elevated MMP-2 has also been found in
atherosclerotic plaques of coronary arteries12.
In view of this we have evaluated the distribution of MMP-2
promoter gene polymorphism by PCR- RFLP and the concerned
phenotype (MMP-2) was analyzed by using ELISA.
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REVIEWOF LITERATURE
Coronary heart disease has been known as impairment of
function of heart due to insufficient blood supply to the heart.
Atherosclerosis is a multifactorial disease. The risk of coronary artery
disease is associated with an individual’s genetic and environmental
factors.13. A large number of studies such as the Framingham heart
study14, the Helsenki Heart study, have been conducted to examine
the role of risk factors for coronary artery disease. The risk factors
identified by these epidemiological studies include a group of
modifiable risk factors like blood lipid profile abnormalities,
hypertension, physical inactivity, obesity, cigarette smoking, alcoholism,
diabetes mellitus, hyper homocysteinemia. Though overwhelming
evidence particularly that given by “Response to retention hypothesis”
indicates that the whole sequence of events is found to be initiated
by the retention of modified Low Density Lipoprotein15,16, it was
recongnized that lifestyle changes and the use of new pharmacologic
approaches to lesser plasma cholesterol17,18, Cardiac disease continues
to be the main cause of death. The background trigger for
atherosclerosis like structural changes of blood vessels is hidden ,
which has to be emphasized.
ATHEROSCLEROSIS
Atherosclerosis is a disease of arterial blood vessels. It is mainly
due to accumulation of inflammatory cells such as macrophages, white
blood cells promoted by small low density lipoproteins without
adequate removal of fats and cholesterol from the macrophages by
functional high density lipoproteins . It is commonly referred to as a
“hardening” of the arteries leads to formation of numerous plaques
within the arteries.
The lesions of atherosclerosis occurs mostly within the
intimal layer of the artery wall. They inlcude19-20,
• Fatty streak
• Fibrous plaque
• Complicated lesions
o Plaque disruption
o Athero thrombosis
FATTY STREAK
The process of atherogenesis begins in childhood with the
development of fat, lipid rich lesions called fatty streaks. They are
also found to contain macrophages, T lymphocytes, smooth muscle cells
– each of these cells are found to be loaded with cholesterol. The lesions
are yellowish and sessile in appearance and they cause little
obstructionof the affected artery. Lipid deposition does not lead to
the complex lesions of atherosclerosis but progression of disease is
associated with that a number of factors resulting the formation of
fibrous plaque.
FIBROUS PLAQUE
It is otherwise called as fibromusculoelastic consists of proliferated
smooth muscle cells,connective tissue with little lipid and that the deep
core of lipid and cell debris results from insufficient blood supply,
inflammation, and cell necrosis. A fully blown fibrous plaque consists
of many smooth muscle cells lined by a dense connective tissue matrix
often intermixed with numerous macrophages.
ADVANCED LESIONS – PLAQUE DISRUPTION AND
ATHEROTHROMBOSIS
The typical advanced, complicated lesion contains a large
necrotic core with a fibrous core, loaded with macrophages. The
macrophages can from numerous proteolytic enzymes, including
metalloproteinases – these enzymes cause the removal of fibrous cap –
by plaque disruption and thinning of fibrous cap. The plaque disruption
allow the lesion to get involved in thrombotic episodes that can lead to
occlusive disease21.
Thus,events atherosclerosis include, causes
1. First, the rupure of atheromatous plaques, lead to stenosis of the
artery therefore, an inadequate blood supply to the organ.
2. Second, formation of aneurysm occurs if the compensating artery
enlargement process is extreme.
The rupture of the plaque exposes its thrombogenic contents into
the lumen that will rapidly slow the blood flow, leading to death of
the tissues fed within 5 minutes. This catastrophic event is known
as infarction.
The clinical scenario of this catastrophic event depends on
which artery is affected by this event.
1. Thrombosis of a coronary artery, causing myocardial infarction
is called as Coronary artery disease.
2. Second most common is that caused due to thrombosis of
carotid artery branches and inadequate blood supply to brain –
which presents itself as stroke or transient ischemic attack.
3. Peripheral artery disease caused by insufficient blood supply to
the legs, typically due to a combination of both obstruction s and
aneurysm .
4. Arteries of the intestines, kidneys, legs, are also affected.
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HYPOTHESIS OF ATHEROGENESIS
It has been recognized in human for thousands of years. Long
has discussed the development of clinic-pathologic correlations that
allowed the formulation of a hypothesis relating the grading of
atherosclerosis to the frequency of myocardial infarction and stroke22.
Virchow proposed the idea that degenerative lesion of atherosclerosis
some form of injury to the arterial wall related with the inflammatory
responses. 23. This idea was later customized by Antischkow24 and the
part of platelets and thrombus formation in atherosclerosis is included by
Duguid25. The endothelial lining26, of the artery is a key element in
the maintenance of normal arterial function is distinguished by John
French.
RESPONSE TO INJURY HYPOTHESIS
Endothelial cells provide thromboresistance surface that promotes
the continuous flow of blood throughout the vascular tree 27,28,29,30,31.
Smooth muscle cell migration and proliferation is mediated by various
cytokines. Small plasma lipoproteins are transported by endothelial cells
into the arterial all32. The endothelium exhibits the thromboresistant
characters by production of three factors. They are the cell surface
glycoproteins and proteoglycans that form the surface coat of the
endothelial cells, prostacyclin30, and the most potent agent, nitric
oxide31. Prostacyclin and NO are potent vasodilatory agents and
potent inhibitors of platelet aggregation. The hypothesis posits that
some form of “ injury” to the endothelium causes alteration in
structure and function of the endothelial cells. So that the
lipoproteins and inflammatory cells are more easily penetrate into
the artery wall.
The alteration of endothelium is associated with overexpression
of E, L, P selectin that appear to play a role in inducing rolling and
attachment of monocytes and T lymphocytes to endothelium. This
rolling is facilitated by the upregulation of ICAM 1 and VCAM 1
also. Another molecule formed by endothelium, PeCAM 1 has been
shown to participate in interendothelial migration by the adherent
leukocyte into the subendothelial space or intima of the artery.
Thus, the earliest phase of the chronic, inflammatory response that has
become recognized to be the hallmark of atherogenesis is represented by
leukocyte adhesion due to the formation of these attachment and
adherence molecules on the surfaces of the endothelium and the
leukocytes32-36.
A second event accompanying endothelial dysfunction is
transmigration of lipoproteins particularly of small LDL particles, this
transmigration places LDL in the subendothelial space which is virtually
devoid of any antioxidant properties of the circulation, hence it gets
oxidized. Oxidized LDL can act as chemotactic reagent. The monocyte
gets activated to macrophages, which express SR-B1 causing
unregulated uptake of LDL particles, forming foam cells. Such a lesion
with foam cells, activated inflammatory cells is called as fatty streak.
Oxidised LDL, foam cells, the activated macrophages, T-cells,
produce various cytokines IL-1, TNF-α, Under the influence of these
cytokines, endothelium, macrophages and T cells produce PDGF,
FGF58. PDGF facilitates the movement and proliferation of smooth
muscle cell. FGF stimulates the vascular smooth muscle cell to produce
collagen and the various components of extracellular matrix together
they form the fibrous cap. TNF-α induces apoptosis of foam cells
causing exocytosis of its lipid content, which forms the lipid core.
Such a lesion with lipid core, surrounded by activated T-cells,
macrophages, platelets, lined by a fibrous cap is called as a stable
atherosclerotic plaque. Thus oxidized LDL is not only toxic to the
endothelium and the surrounding cells in the intima but also
chemotactic for monocytes and can activate monocyte derived
macrophages to produce growth factors and cytokines. Hence it may be
the principal culprit in advancing the lesions of atherosclerosis.
All these lesions would be reversible and, reversed back to normal
if the endothelial injury is self –limited. But when it is constant over
period of many years, the lesion continues to progress, and becoming
more complex. Because, the atherosclerotic plaque does not only have
smooth muscle cells but also macrophages, which are capable of
producing metalloproteinases and TNFα, both of which cause
necrosis and digestion of the fibrous cap, this loss of fibrous cap is
responsible for the complications of atherosclerosis, namely plaque
rupture. This plaque rupture exposes the subendothelial extracellular
matrix to the factors of coagulation in the circulation initiating the
intrinsic pathway of coagulation – this is responsible for
atherothrombosis.
FACTORS INFLUENCING ATHEROGENESIS
UNMODIFIABLE RISK FACTORS
1. Age
2. Male sex
3. Socioeconomic status
MODIFIABLE RISK FACTORS
1. Cigarette smoking
2. Alcoholism
3. Insulin resistance & hyperglycemia
4. Hypertension
5. Obesity
6. Oxidative stress
7. Abnormal lipid profile
a. High total and LDL cholesterol
b. Low HDL cholesterol
c. High triglycerides
d. Lipoprotein(a)
8. Physical inactivity
Age
In many epidemiologic surveys, age remains one of the strongest
predictors of disease. The majority of patients with atherosclerotic
coronary heart disease are more than 65 years old. Older patients have
higher mortality and more complications. Age related changes in the
cardio vascular system and other organs make it reasonable to assume
that aging per se constitutes a major reason for the increased morbidity
and mortality in older persons. These age related changes include
diastolic dysfunction, degenerative changes in the conduction system,
reduced responses to catecholamine and sympathetic stimuli.
Male sex
The relationship of gender to the development and prognosis of
atherosclerotic coronary heart disease is complicated37. The powerful
protective effect of the premenopausal state in preventing and postponing
the condition is fully appreciated; women tend to develop atherosclerotic
coronary heart disease approximately 10 years later than men. In women
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under the age of 60 epicardial coronary atherosclerosis is uncommon38.
Complications are fewer in women after the onset of angina, but they
may be more frequent after myocardial infarction39,40. However there are
multiple reports indication a gender bias in reference to the use of
diagnostic and therapeutic procedures, but interpretation is
complicated by the possibility of overuse and overtreatment in low risk
men41-45. The point has been made clearly. Atherosclerotic coronary heart
disease manifest as angina, infarct, and sudden death is as common in
women after age 60 as it is in men.
This gender dependent differential risk is attributed to the
protective function exerted by estrogens. Recently, a study of estrogens
and their effect on smooth muscle cells and the other elements of
atherogenesis showed that estrogens have an antiproliferative effect on
smooth muscle cells and can be protective to the endothelium in
relation to stimulation by growth factors, cytokines and other agents.
Estrogen is not only antiproliferative for smooth muscle but also has
been shown to be capable of modulating acetylcholine mediated
dilation of atherosclerotic coronary arteries46.
Family history of Early – Onset CHD
Over 35 case-control and prospective studies have consistently
indentified an association between CHD and a history of first degree
relatives with early onset CHD47. This risk generally persists even
after adjustment for other risk factors. The family history most
predictive of coronary disease is that of a first degree relative developing
CHD at an early age. Positive family history70 denotes when male with
disease at 55yrs or less and female with onset at 65yrs or less. The
larger the number of relatives with early onset of CHD or the younger
the age of CHD onset in the relative, the stronger the predictive
value49,50.
Socioeconomic status
A consistent relationship has been devised between lower
socioeconomic status and atherosclerosis. There has been the perception
that conventional risk factors cluster in lower socioeconomic groups
and that this phenomenon can explain the increased incidence of
atherosclerotic coronary heart disease51. But, only 50% of atherosclerotic
coronary heart disease can be explained by known risk factors. The
socioeconomic status proved to be independent predictors in patients with
established atherosclerotic coronary heart disease52. Although no simple
relationship between socioeconomic status, risk for cardiovascular
disease and long term outcome for manifest atherosclerotic coronary
heart disease can be devised, the evident is consistent and persuasive
that lower socioeconomic status is an independent and significant
determinant of long-term outcome.
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Hypertension
Epidemiological studies have established found that both systolic
and diastolic bloodpressure have a positive and graded correlation to
CHD53,54.55. The risk imposed by hypertension is increased substantially
when other risk factors are present. Hypertension clusters insulin
resistance, hyperinsulinemia, glucose intolerance, dyslipidemia, left
ventricular hypertrophy and obesity and occurs in isolation in fewer than
20% of individuals56.
The potential mechanisms by which hypertension may cause
impaired endothelial function include increased endothelial permeability
to lipoproteins, increased adherence of leukocytes, increased oxidative
stress, and hemodynamic stress that may trigger acute plaque rupture, all
these mediated by initiation of NF-kB pathway and inactivation of
eNOS enzyme.
Hyperglycemia
Hyperglycemia is an independent risk factor for CHD, increasing
the risk by two to three times for men and three to five times for
women57. CHD is the leading cause of death in diabetic patients and
approximately 25% of MI survivals have diabetes58. The CHD risk for a
premenopausal diabetic woman is similar to the risk of a nondiabetic
man,hence diabetes abolishes the protective effect of being a
premenopausal female59. Diabetic women have twice the risk of
recurrent MI compared with diabetic men60. The greater risk of CHD in
diabetic women compared to diabetic men may be explained in part by
the greater adverse effect of diabetes on lipoproteins in women61.
Potential mechanisms by which hyperglycemia may cause
atherosclerosis include impaired endothelial function, glycation of
LDL, enhanced lipoprotein oxidation, increased fibrinogen, increased
platelet aggregation, impaired fibrinolysis, increased small LDL. All
these are attributed to the increased flux of glucose into glycolysis
(glucose uptake and hexokinase activity in endothelium is insulin
independent), as a result there is an increased NADH/NAD ratio, causing
increased flux of electrons through electron transport chain, producing
superoxide radicals. This causes DNA damage and the resultant ADP
ribosylation of proteins inhibit glyceraldehyde 3-phosphate
dehydrogenase of glycolysis, causing accumulation of glyceraldehyde
3- phosphate and its precursor fructose 6-phosphate. The former cause
activation of protein kinase C pathway through DAG – protein kinase C
pathway stimulates the production of various cytokines and thereby
stimulates inflammation. Fructose 6 phosphate stimulates hexosamine
pathway, thereby stimulate N- glycosylation of many proteins like eNOS
and inhibition of them, this causes NOS uncoupling and the resultant
oxidative stress further aggravates the condition. Furthermore, there is
increased formation of advanced glycation end product, which on
binding to receptor for advanced glycation end products is found to
stimulate NF-kB pathway, causing all the features of atherosclerosis.
Insulin resistance and hyperinsulinemia
Coronary risk factors are resistance to insulin, hyperinsulinemia ,
hypertension, diabetes, hypertriglyceridemia, low HDL, predominance of
small LDL, and elevated plasminogen activator inhibitor
concentration62,63. Hyperinsulinemia may raise blood pressure through
sympathetic nerve stimulation and/or renal sodium retention. Insulin
sensitivity is associated with endothelial nitric oxide production in
healthy persons providing a clue as to how insulin resistance may
promote CHD directly64. Furthermore, hyperinsulinemia has been found
in a prospective study to be an independent risk factor for CHD in
nondiabetic men after adjusting for body weight, blood pressure and
dyslipidemia65.
Physical inactivity
Physical inactivity roughly doubles the risk of CHD. Moderate
intensity exercise decreases coronary atherosclerosis and widens coronary
arteries in monkeys fed on atherogenic diet compared with monkeys fed
the same diet but forced to be inactive66.There is a slow development of
angiographically defined coronary atherosclerosis in human with physical
activity67. Men with physical fitness have reduce the risk of CHD68. The
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risk of MI and sudden cardiac death is greatest during exercise, leading
some to question the benefits of exercise69. The overall risk of myocardial
infarction and sudden cardiac death, is however low among those who
exercise regularly. The greatest reduction in risk is between
sedentary individuals and those who do regular moderate intensity
activity.
Physical activities may lessen CHD risk include by rising HDL,
decreasing hypertension and obesity, reducing insulin resistance,
decreasing platelet accumulation and increasing fibrinolysis68.
Obesity
Obesity promotes insulin resistance, hyperinsulinemia,
hypertriglyceridemia, low HDL cholesterol, and LVH70,71. Many
observational studies have found that obesity strongly and positively
correlates with the risk of CHD in univariate analysis. In
multivariate analysis, when controlling statistically for risk factors
such as hypertension, diabetes, and dyslipidemia, obesity is not found to
be an independent risk factor. Rather it reflects that much of the adverse
consequences of obesity are mediated through resultant metabolic risk
factors acting as pathological links in the causal pathway. Nevertheless,
some large prospective observational studies of long duration indicate
that obesity also increases coronary and cardiovascular mortality in men
and women72-74. The deposition of fat in central portions of the body
predicts CHD in men independently of body-mass index and other
major risk factors75. Weight loss improves insulin sensitivity and glucose
disposal; reduces blood pressure, triglycerides and LVH; and increases
HDL cholesterol70,71.
Oxidative stress
Over production of reactive oxygen species has been
concerned to play a major role in a number of cardiovascular
pathologies. ROS are generated in vascular cells by NADPH oxidases,
uncoupled eNOS, and as a product of mitochondrial respiration37. If
this production goes unbalanced, it leads to exacerbation of
pathophysiological processes. Superoxide radicals are found to cause
oxidative modification of LDL. Oxidised LDL, by activating NF-kB
pathway of inflammation is found to mediate the increased production
of IL-1, increased expression of ICAM, both of which mediate the
rolling of inflammatory cells. Furthermore there is increased
production of PDGF and FGF, both of which cause smooth muscle cell
proliferation and migration. This cycle is reinforced by the decreased
production of NO, because the superoxide cause nitrosylation of
eNOS and thereby it inhibits the enzyme activity. The decreased NO
causes increased vascular reactivity and the resultant shear stress will
further stimulate NF-kB pathway. Thus, commencement and
development of atherosclerosis is influenced by oxidized LDL76-79 .
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Cigarette smoking
Strong dose relationships between cigarette smoking and
coronary heart disease have been observed in both sexes. Cigarette
smoking increases the risk two to three fold and interacts with other
risk factors to multiply risk. Pathophysiological studies have identified
a panoply of mechanisms through which cigarette smoking may cause
CHD. Smokers have increased levels of oxidation products, including
oxidised LDL. Cigarette smoking also lowers the cardioprotective
levels of HDL. These effects, along with direct effects of carbon
monoxide and nicotine, produce endothelial damage. Possibly, through
these mechanisms, smokers have increased vascular reactivity80.
Cigarette smoking is also related to increased levels of fibrinogen81 and
increased platelet aggregability82. Thus cigarette smoking paves way for
atherosclerosis by inducing oxidative stress and by altering
coagulability.
Dyslipidemia
Total cholesterol and LDL cholesterol
Many studies have identified a permanent, graded and direct
association between serum cholesterol and CHD occurrence.83. The
level of total and LDL cholesterol interacts with other risk factors to
multiply risk84. Elevated LDL cholesterol levels have been related to
recurrentevents and CHD death in patients with established CHD85. The
progression of atherogenesis is mediated by increased LDL cholesterol
levels. Elevated cholesterol concentrations in the plasma lead to an
increased release of LDL particles into the arterial wall. Their oxidation
leads to the formation oxidized LDL which act as chemoattractants86.
LDL is also a potent mitogen for smooth muscle cells; progressive
growth of atherosclerotic plaques can be halted by lowering of LDL
cholesterol levels. Atherosclerotic plaques with a large lipid core and
numerous lipid filled macrophages are prone to rupture87.
Furthermore, small dense LDL is felt to be more atherogenic88.
Possible explanation for this is that when a person has more of
small LDL particles, for given cholesterol content, the number of LDL
particles will be more, and an LDL receptor can accept only one LDL
particle at a time and hence the rate of metabolism of LDL is
decreased, causing accumulation of LDL in the plasma. The second
reason for the same is the endothelium will be more permeable to small
LDL particle when compared to a normal LDL.
Triglycerides
The relationship between triglycerides and CHD has been less
clear. This relationship usually disappears after adjustment for other risk
factors such as HDL cholesterol, obesity and diabetes89.
Hypertriglyceridemia however has been found to be an independent risk
factor in women90. Several mechanisms have been proposed to explain
the triglyceride- CHD association. First, some patients with
hypertriglyceridemia have a predominance of small, dense LDL
particles. Second, fasting hypertriglyceridemia may be a marker of
exaggerated postprandial hyperlipidemia, which may promote the uptake
of atherogenic triglyceride rich lipoprotein remnants by endothelial
cells91. Finally, serum triglyceride levels are strongly related to
fibrinogen and factor VII in numerous epidemiological studies92.
Therefore, number of mechanisms, direct and indirect link serum
triglycerides and CHD.
Low HDL cholesterol
There is indirect association between HDL cholesterol levels
and the frequency of CHD93. The ratio of total cholesterol to HDL
cholesterol is a superior interpreter of CHD than the HDL
cholesterol level alone93. Two important mechanisms by which HDL is
thought to play a protective role against atherosclerosis are reverse
cholesterol transport and inhibition of LDL oxidation.
MMP-2
MMP-2 is a zinc and calcium dependent endopeptidases94.
MMP-2 has MW of 72KDa, is also known as type IV collagenase that
degrades native type IV, V, VII, and X collagen95 .. Type IV is a main
component of the basement membrane. MMPs are zinc dependent
endopeptidase, able to cleave the ECM. ECM plays a key role for
the proper function of different organs of the human body including heart
and blood vessels. MMPs cause proteolytic destruction of ECM96.
Because of its presence everywhere in the body , it has various
functions.97 Gelatinases composed of the 72KDa MMP-2 and 92KDa
MMP-7. Gelatinase A is an other name of MMP-2.
All MMPs are produced in inactive structure. They are
produced as proenzymes and need extracellular activation. For its
activation MMPs need zinc . The activation steps consist of three
different mechanisms:1. stepwise activation, 2.cell surface activation
and 3. intracellular activation.
These enzymes are produced in low amounts by normal cells
linked with normal tissue remodeling such as healing of wounds,
implantation, invasion of trophoblasts, and angiogenesis . MMPs are
often over expressed in malignant tumors .
The matrix metalloproteinase family.
MMPs-MMP-1
Name-Fibroblast
Subfamily-Interstitial
Mainsubstrate -Fibrillar collagen
MMPs-MMP-8
Name-Neutrophil
Subfamily-- Collagenase
Main substrate-Fibrillar collagen
MMPs-MMP-13
Name--- Collagenase-3
Subfamily-- Collagenase
Main substrate-Fibrillar collagen
MMPs-MMP-18
Name--- Collagenase-4
Subfamily-- Collagenase
Main substrate-Fibrillar collagen
MMPs-MMP-2
Name--- Gelatinase
Fig6.RIBBON DIAGRAM OF HUMAN PRO MMP-2 AND
ACTIVE MMP-2
Fig. 6. (A) Ribbon diagram of human proMMP-2 and active MMP-2.
The pro-domain is shown in red, catalytic domain in pink, the
linker region in yellow, the hemopexin domain in green, zinc ions in
purple, calcium ions in grey. The dotted circle indicates the region
where the catalytic and hemopexin domains intereact. proMMP-2 has
a larger area of
Contact sites than MMP-2. This results in the active form has an
‘‘open’’ configuration compared the ‘‘closed’’ configuration of
proMMP-2. (B) Ribbon structure of the complex of proMMP-2 and
TIMP-2. Domains of proMMP-2 are shown as in (A) and the
finbronectin type II (FNII) motif is in purple.
Subfamily-Gelatinase A
Main substrate- Gelatin,Type IVcollagen.Fibronectin.Elastin,Laminin
MMPs-MMP-9
Name--- Gelatinase
Subfamily- Gelatinase B
Main substrate- Gelatin,Vitronectin,.Fibronectin.Elastin,Laminin
MMPs-MMP-3
Name--- Stromelysins
Subfamily- Stromelysins-1
Main substrate-Fibronectin,TIMP-2
MMPs-MMP-10
Name--- Stromelysins
Subfamily- Stromelysins-2
Main substrate- Fibronectin,TIMP-2
MMPs-MMP-11
Name---Stromelysins
Subfamily- Stromelysins-3
Main substrate- Gelatin,.Fibronectin.Elastin Laminin,Aggrecan.
MMPs-MMP-7
Name--- Matrilysin
Subfamily- Stromelysins
Main substrate- Gelatin,.Fibronectin.Elastin ,Vitronectin,Aggrecan
MMPs-MMP-12
Name--Metallo- Elastases
Subfamily---- Elastases .Main substrate- Gelatin,.Fibronectin,Elastin,
Vitronectin,Proteoglycan,Collagen-IV
MMPs-MMP-14
Name—MT1-MMP
Subfamily---- Membrane type MMPs
Main substrate- Pro MMP-2,Pro collagenase
MMPs-MMP-15
Fig7.DOMAIN STRUCTURE FOR MAJOR CLASSES OF MMPs
Figure 7. Domain structure for the major classes of MMPs. Major domains
include the signal peptide (SP), prodomain (Pro), catalytic domain with the
active site zinc (Zn) bound to cysteine residues within this domain and "cysteine
switch-residue" in the prodomain, the hinge domain (HG), the hemopexin
domain, and in some cases either a transmembrane domain or GPI-anchor
domain (GPI). A furin cleavage site between the prodomain and the catalytic
domain is found in some MMPs. In the gelatinases, fibronectin-like type II
repeats (FN) are also present
Fig 8. DOMAIN STRUCTURE OF MMP-2
Domain structure of the MMP2.
 Pre: signal sequence;
 Pro: propeptide with a free zinc-ligating thiol (SH)
group;
 Zn: zinc-binding site;
 II: collagen-binding fibronectin type II inserts;
 ;
The hemopexin/vitronectin-like domain contains four
repeats with the first and last linked by a disulfide
bond.
 H: hinge region;
Name—MT2-MMP
Subfamily---- Membrane type MMPs
Main substrate- Pro MMP-2,
MMPs-MMP-16
Name—MT3-MMP
Subfamily---- Membrane type MMPs
Main substrate- Pro MMP-2,
MMPs-MMP-17
Name—MT4-MMP
Subfamily---- Membrane type MMPs
Main substrate- Nil.
Other MMPs-MMP-19
MMP-20(Enamelysin),Substrate-Amelogenin.
SYNTHESIS OF MMP-2
MMP-2 are produced by endothelial cells, smooth muscle cells,
and fibroblasts. Oxidative stress which is involved in cardiovascular
disease, can stimulate MMPs production and activation98. MMP-2 is
the principal matrix metalloproteinase secreted by smooth muscle
cells. Most MMPs are produced as inactive zymogens. The
majority of MMPs contain propeptide domain with a unique and highly
conserved sequence of cysteine (‘cysteine switch’) is capable of binding
zinc in the catalytic domain, and making the enzyme inactive99.
Interruption of the cysteine- zinc bond and deletion of the propetide
domain activates the catalytic domain. It also needs calcium ions for
its activation . The C- terminal hemopexin like domain has a role in
substrate binding100. Pro MMP-2 contains 631 aminoacid residues.
Active MMP-2 contains 80 aminoacid residues.
ACTIVATION OF MMP-2
Activation of inactive enzyme can occur intracellularly, at the
cell surface, and in the extra cellular space through the activation by
previously activated MMPs through a course called stepwise
activation101. The signals for endoproteolytic cleavage for furin via trans
–Golgi network are considered to be from these MMPs which contain
a motif of basic aminoacid sequence present in upstream of the
catalytic domain102,103.
At the cell surface Pro-MMP-2 binds with MT1-MMP and TIMP-
2, and the neighbouring MT1-MMP cleave Pro-MMP-2 at the
prodomain104.
Fig9.ACTIVATION OF PRO MMP-2
Figure 9. Simple model illustrating the basic steps of proMMP-2
activation through the formation of a proMMP-2/TIMP/MT-MMP
ternary complex. In this model, TIMP-2 or TIMP-3 binds the catalytic
domain of MT1-MMP or MT3-MMP forming a TIMP/MT-MMP
complex on the cell surface. While this inhibits the activity of the
occupied MT-MMP, TIMP-2 and TIMP-3 retain their ability to bind
proMMP-2 effectively recruiting proMMP-2 to the cell surface. Once
on the cell surface, an adjacent TIMP-free MT-MMP cleaves and
activates proMMP-2.
The integrin binds to the hemopexin domain of Pro-MMP-2 is
considered to be the initiation of activation. Many integrins including
2 β1 and 2 β3 are involved. Some proteases, mainly plasmin, is the
major contributor for extra cellular stepwise activation via cysteine
switch105. Reactive oxygen compounds react with thiol groups and
activate Pro-MMP-2 are thought to be via the ‘cysteine switch’
mechanism106.
Thrombin, and factor Xa are also involved in activation of Pro-
MMP-2. Activated MMP-2 activates Pro-MMP-9 and MMP-12
thereby causing a cascade-like effect on MMP activation107. MMP
activity is also regulated by tissue specific inhibitor of
metalloproteinases 108(TIMP-1, TIMP-2, TIMP-3, TIMP-4).
FUNCTIONS
MMP-2 has numerous functions including embryonic
development, cell migration, wound healing, tissue resorption and angio
genesis109. All these are due to its ability to modify the structural
integrity of tissues. MMP-2 also involved in osteoblast bone formation
and inhibits osteoclastic bone resorption110. Incresaed MMP -2 expression
is found in the pathologic conditions, such as rupture of atherosclerotic
plaques and following acute coronary syndromes111.
Fig 10. INTRACELLULAR ACTIVATION OF PROMMP-2
ECM plays a key role for the proper function of different organs of
the human body including heart and bloodvessels..
The main function of MMP-2 is destruction of proteins in
ECM such as type IV, V, VII, IX and X collagen.
REGULATION OF MMP-2 ACTIVITY
There are three different levels for MMP-2 regulation. 1. Gene
transcription, 2. Post translational activation of zymogens and 3.
Interaction of secreted MMPs with inhibitors112. Inter relation of
transcription factors, co-activators and co-repressor proteins with cis-
acting elements in the promoter region of MMP-2 gene involve at the
level of transcription. It is predominantly via prostaglandin E2 -cAMP
dependent pathway. G proteins have been concerned to be involved113.It
is stimulated by inflammatory cytokines, hormones, and growth factors,
such as interleukin-1β (IL-β), IL-6, tumor necrosis factor114 – 117.
Hypoxia, more than 24 hrs, increases expression of mRNA for MMP-2.
Transcriptional regulation of MMP-2
Indomethocin, corticosteroids, and interleukins 4118,119,120reduce
gene expression. Their inhibition is due to addition of PGE2 or cAMP.
PPAR released from vascular smooth muscle cells and macrophages
decreases MMP expression121 .T to C alteration at a site – 1306 in
the promoter region of MMP-2 gene influences expression. This
polymorphisms have been linked with cardio vascular disease.
ROLE OF MMP-2 IN ATHEROSCLEROSIS
MMPs cause plaque progression of plaque make it into
vulnerable , and more prone for rupture. Inflammation, is a hall
mark of atherosclerotic plaque. Atherosclerotic lesion develops in the
course of a chain of highly specific cellular and molecular
inflammatory response of the vessels wall to an initial injury. The
initial lesion, principally producing dysfunction of endothelium.
Endothelium tries to neutralize this initial damage but when it persists
the inflammation is characterized by penetration of leukocytes,
lymphocytes, macrophages, and smooth muscle cells into the vessel wall
along with lipids. These abundantly produced and activated MMP-2
assist the access of smooth muscle cells, monocytes, macrophages
through endothelial cell layer by degrading the basement membrane.
Simultaneousely along with the ingestion of cholesterol, the
development of plaque in the vessel wall is initiated and the plaque
grows122,123 resulting reversible fatty-streak lesion. In the sub intimal
space, MMP-2 activity further boosted by inflammatory cytokines such
as interleukin-1, TNF-, and oxidized LDL resulting non reversible
lesion consist of activated macrophages, foam cells, T lymphocytes,
 Fig 11.ROLE OF MMP-2 IN ATHEROSCLEROSIS
mastcells and other such cells around a necrotic lipid rich core. Thin
fibrous cap lines over the plaque separates it from the blood stream.
The activated macrophages and mast cells locally destabilize
the plaque by secreting a variety of matrix – degrading proteolytic
enzymes such as MMPs124,125,126 and causes dissolution of fibrous cap
resulting rupture of plaque.The exposed thrombogenic substances into
the lumen leading thrombosis and its complications.
MMP-2s are again involved and can have ambivalent
functions. The fibrous cap also contains elastin and
proteoglycans127,128. Degradation of the ECM by MMPs can thin the
fibrous cap and reduce the collagen content – typical features of
vulnerable plaques prone to rupture129. MMPs also promote plaque
angiogenesis, another feature associated with vulnerable plaques130.
Facilitation of cell entry, destruction of ECM proteins, thinning of
fibrous cap and angiogenesis mediated by MMP-2 crucial for the
progression of plaque towards vulnerable, high-risk lesions. MMPs
causes dissolution of fibrous cap and destabilization of atheromatous
plaque resulting plaque rupture. Subsequently, exposes thrombogenic
substance into the lumen resulting thrombosis and its
complications.
Increased activation of MMP-2 in coronary plaques,
associated with plaque clacification131,132,133.. Besides local expression in
Fig12.ROLE OF MMP-2 IN PLAQUE RUPTURE
plaques, circulating MMP-2 found in patients with myocardial
infarction134.
Additional evidence linking MMPs to plaque rupture is by cyclo
oxygenase pathway. MMP-2 production by macrophage also occurs
through a PGE2/cAMP- dependent pathway135.
MMP-2 AND PLATELET AGGREGATION
Translocation of MMP-2 from the cytosol to the platelet
surface and is released during platelet aggregation136. vWF –
induced GP Ib expression is mediated by MMP-2 and causes
platelet adhesions137. The pro-aggregatory effects of collagen and
platelets are initiated by MMP-2 via the mechanism independent
of aspirin and thrombaxane138. It is thought to be beneficial that
selective MMP-2 inhibitors could be given along with existing
antiplatelet therapy in acute coronary syndrome.
ENDOGENOUS INHIBITORS OF MMP-2:
Activities of MMP-2 are inhibited by two types of
endogenous inhibitors 1. α2-macroglobulin and 2.TIMPs . Human α2-
macroglobin is a 725 kDa MW and it has four 180kDa identical
subunits similar to MMP-2. It acts by entrapping the proteinase
within the macroglobulin and the complex is easily cleared by
the receptor -mediated endocytosis .
TIMPs, consisting of 184–194 amino acids , are subdivided
into an N-terminal and a C-terminal sub domains. Three conserved
disulfide bonds present in both domains, and the N-terminal domain
fold act as an independent unit with MMP inhibitory activity.
MMP-2 GENE
MMP-2 gene is located at chromosome 16q21, size 27, 862
bases. Base pair starts from 55515474 and ends at 55540586 base
pair. The DNA sequence contains 13 exons. . MMP-2 gene spans
17kb and contains 13 exons encoding a 72KDa protein, ~ 3.1kb of
MMP-2 transcribed sequence, 1.9kb of promoter sequence, and ~ 1kb
of intronic sequence.
MMP-2 GENE POLYMORPHISM
MMP-2 gene polymorphism is situated at the promoter region
linked with transcription. Price et al described this -1306 C/T MMP-2
polymorphism recently. They confirmed that C for T transition at location
-1306 was functional and the C allele was linked with the more
promoter activity.
It is a functional single nucleotide polymorphism140. -1306 C
transition in the MMP-2 promoter sequence distrupts at SP1-type
promoter site (CCACC box), and thus displays a strikingly lower
promoter activity with the T allele. -1306 C > T polymorphism affect
Fig13.MATRIX METALLOPROTEINASE-2 GENE
LOCUS 16q21
binding of the estrogen receptors and the SP1 transcription factor
respectively141. In the MMP-2 gene [rs 243865: -1306C/T, and rs
2285053: -735C/T] there are two promoter region polymorphisms .
The gene transcription and the enzymatic levels are altered by
producing disruption of transcriptional regulators binding sites 142. In
the MMP-2 gene, the two C 735 T and C 1306 T are frequently present.
They produce allele specific effects on the transcriptional activities of
MMP gene promoters143.
MMP-2 GENE POLYMORPHISM AND MMP-2 ACTIVITY.
Among individuals MMP-2 expression can vary due to
genetic difference which could influence susceptibility to cardio
vascular disease. Raised MMP-2 levels have been found in the
plasma of MI patients144. Atherosclerotic plaques of coronary artery
contain increased concentrations of MMP-2. In plasma MMP-2
concentration increase slowly after onset of MI, and reaches the
maximum on day 21. The increased MMP-2 levels by the -
1306CC genotype polymorphism becomes more significant and
represents more MI risk145.
POLYMORPHISM
The human genome contains hundreds of variations in base
sequences that do not affect the phenotype .The property of molecules
to exist in more than one form is known as polymorphism.
Polymorphism occurs in the frequency of more than 1%
population.
MUTATION
A mutation is defined as an change in nucleotide
sequence of DNA .This may be either gross ,so that large areas
of chromosome are changed , or may be subtle with change in one
or a few of every 106 cell divisions, one mutation takes place.
Mutation may be defined as an abrupt spontaneous origin of new
character. Statistically, out of every 106 cell divisions, one mutation
takes place. Mutation occurs in the frequency of less than 1% of
population.
DIFFERENCE BETWEEN MUTATION AND DNA
POLYMORPHISM
If more than 1% of the population has a particular alteration
in the sequence ,it is polymorphism. If only a few individuals have
it, then it is mutation. Polymorphism is normal variation, and generally
having no deleterious effect. Mutation is abnormal ,and sometimes
will have defective function.
A polymorphic gene is one , in which the variant alleles are
common in more than 1% of the total population. The existence of
two or more types of restriction fragment patterns is called
restriction fragment length polymorphism (RFLP). This can be used
as a genetic marker.
INHIBITORS OF MMP-2 EXPRESSION
In a concentration-dependent manner doxycycline inhibits
expression of MMP-2 from smooth muscle cells. It reduces significantly
MMP-2 production from SMCs at normal therapeutic serum
concentration(5 µg/mL . It decreases half-life of mRNA from 49 hours to
28 hours, there by reducing MMP-2 mRNA stability. Doxycycline
acts by binding to metal ions such as calcium and zinc and
inhibits the MMP-2 expression.
OTHER DISEASES ASSOCIATED WITH MMP-2 GENE
POLYMORPHISM.
Many polymorphisms in the promoter region of MMP-2
gene, affects the MMP-2 production in an allele-specific manner.
All these functional polymorphisms are associated with the risk of
nasopharyngeal carcinoma. There is notably raised susceptibility to
NPC for the MMP2 -1306CC (rs243865:C>T) and -735CC
(rs2285053:C>T) .The increased susceptibility to NPC related to the -
1306CC and -735CC genotype and the C(-1306)-C(-735) haplotype was
highly marked in heavy smokers. The MMP-2 gene encoding 72-kDa
collagenaseIV is located on chromosome 16q21. Recently, −735C>T
(rs2285053), a sequence variant in the promoter region in MMP-2,
leading to reduced promoter activity and thereby reduced gene
expression, has been associated with gastric cardia . MMP-2 −735C>T,
CT or TT genotype recipients were linked with decreased danger for
allograft rejection .MMP-2 members of the gelatinases subfamily,
have been most widely associated with allograft rejection, suggesting a
significantly increased gelatinase expression at the time of rejection.
Development of tissue remodelling and fibrosis in the renal and liver
allograft has been influenced by MMP-2 . By digestion of ECM
,MMPs initiate tumor development and metastasis in invasive cancers.
MMP-2 easily degrades collagen IV and laminin-5 thereby supporting
the metastatic cancerous cells to pass through by providing necessary
gap .
In papillary thyroid microcarcinoma146 expression of MMP-2
could be used as a prognostic marker.
Many reports showed that raised MP-2 expression and activity
in pre cancer and cancer lesions of uterine cervix147.
Progression of the lung diseases may also associated with
elevated levels of MMP-2 were reported148. .
 -1306 allele with more transcriptional activity was linked
with high risk of cancers including lung , gastric , cardiac and
colorectal cancer149-152.
Over expression of MMP-2 has been reported in breast cancer153.
Over expression has been reported in prostatic cancer154. Over expression
has been reported in cutaneous cancer155. Elevated MMP-2 levels
are linked with development of and MMP-2 activity in aneurysm of
aorta156.
Expression of COX2 and MMP-2 are linked with less
survival in human breast cancer157. Increased MMP-2 levels have
been reported after ischaemic stroke158. Beta-amyloid in neurons is
degraded by active MMP-2 and play a role in Alzheimers disease159.
Expression of MMP-2 In pancreatic duct adenocarcinoma160 there
will be increased expression of MMP-2 has been reported. Multicentric
osteolysis and arthritis syndrome161results from mutation of MMP-2
gene.
  
 
 
Aim of the Study
AIM OF THE STUDY
Dysregulation in matrix metalloproteinase-2 activity plays a
major role in atherogenesis and atherosclerotic plaque rupture, a
disease characterised by difference in susceptibility among people in
any given population. A strong positive relation exists between
plasma matrix metalloproteinase-2 level and the risk of Myocardial
Infarction.
Myocardial Infarction is predominantly due to atherosclerosis of
coronary arteries . MMP-2 degrades extra- cellular proteins and plays
an important role in atherogenesis and atherosclerotic plaque rupture,
resulting thrombosis, and its complications like myocardial infarction.
Available reports addressed on the variability of MMP-2 activity
among people in given population. This variability is attributed to the
various polymorphisms of MMP-2 gene, whose product is suspected to
be involved in pathogenesis of atherogenesis and atherosclerotic plaque
rupture with myocardial infarction.
The candidate gene of this study is MMP-2 gene and the aim of
the study is, to determine the association of MMP-2 gene
polymorphism and the concerned phenotype variation with Myocardial
Infarction.
Materials and 
Methods 
MATERIALS AND METHODS
STUDY POPULATION
CASES
The study sample comprised 100 unrelated Myocardial
Infarction patients (85 male , 15 female ) of Mean age 50.34 + 9.84
years. More than 50% narrowing of at least one of the major coronary
arteries included.. Hospitalized cases with acute attack of Myocardial
Infarction were included.
CONTROL SUBJECTS
Controls were recruited from outpatient department during their
visit for non cardiac cases. Age , Sex and other confounding factors like
diabetes , hyper tension , smoking, alcoholism were matched.
METHODS
Recumbent blood pressure and 12 lead ECG were recorded.
Height and weight were recorded and 5 mL of blood was collected by
intravenous route after fortnight fasting in two test tubes. 2 mL was
heparanised and the remaining 3 mL was collected in EDTA tube.
Heparanised tube was centrifuged at 2000 rpm for 10 minutes and
Plasma was used for mmp-2 activity. EDTA tube was centrifuged at
2000 rpm for twenty minutes to get the buffy coat for DNA
extraction and the plasma was utilized for lipid profile estimation.
BUFFY COAT SEPARATION
Buffy coat was separated by centrifugation of EDTA tubes at 2000
revolutions for 20 minutes. Buffy coat was transferred to 2mL
eppendorf and was used for DNA extraction. Plasma separated was
used for lipid profile estimation.
BIOCHEMICAL MARKERS
Total cholesterol (TC), high density lipoprotein cholesterol
(HDL-c) .Low density lipoprotein cholesterol (LDL-c) and triglyceride
concentration (TGL) Were determined by using enzymatic kits and
XL-300 auto analyzer at Centralized Biochemistry Laboratory at
R.G. G.G.H, Chennai-3.
DNA EXTRACTION BY MODIFIED HIGH SALT METHOD161
DNA EXTRACTION BY HIGH SALT
METHOD
Figure 14. shows,extracted DNA(lane 2 to 8) was tested on 0.8%
agarose gel using 1kbp ladder(lane 1)
Ladder shows 10000,8000,7000,6000,5000,4000,3000,2000,and 1000
bp fragments.
RBC Lysis:
• 400µL of buffy coat in a 2mL eppendorf is mixed with 1.6mL of
0.17M ammonium chloride and mixed by inversion until red cells
are lysed for about 10 minutes.
• The cells are centrifuged at 4000 rpm for 10minutes.
• The white cell pellet is washed with 800µL of 0.17M ammonium
chloride solution. The procedure is repeated till a clear white cell
pellet is obtained.
WBC Lysis
• To the pellet 500 µL of TKM I solution is added. It is centrifuged at
10,000 rpm for 10 minutes.
Nuclear Lysis
• Discard the supernatant. To the pellet add 500 µL of TKM II
solution. To that add 300 µL of 6M Nacl and 50 µL of 10%
SDS.
• Mix well (vortex), Centrifuge at 10,000 rpm for 10 minutes.
• Save the supernatant. Transfer it to 1.5 Ml eppendorf.
DNA Precipitation
• To the supernatant double the volume of 100% ethanol is added.
• The sample is stored at -20◦C for 1 hour.
• Then it is centrifuged at 10,000 rpm for 20minutes at 4◦C in a
refrigerated centrifuge.
• The supernatant is discarded. To this 500 µL of 70% ethanol is added.
The pellet is mixed and centrifuged at 10,000 rpm for 10 minutes
at 4◦C.
• Supernatant is discarded and the pellet is air dried.
Storage
• To the pellet 30 µL of LTE buffer is added and the extracted
DNA is stored at -20◦C for future use.
Identification
• Extracted DNA was identified by 0.8% agarose gel
electrophoresis with a constant voltage of 7V/ cm and comparison
with a known molecular weight 1kb DNA ladder . Figure:1
Concentration of extracted DNA
• Concentration of extracted DNA was estimated using UV
spectroscopy at 260nm. The absorbance at 260nm was 0.0203.
 Concentration was calculated using the formula: 1 OD is equivalent
to 50µg/mL
Conc. of DNA = absorbance × 50µg/mL × dilution factor
= 0.0203 × 50 × 100
= 101.5 ng / µL
• Purity of extracted DNA was assessed by 260/280 ratio and it
was found to be > 1.7
POLYMERASE CHAIN REACTION
• 188 bp fragment of MMP-2 gene was polymerized by using,
• Forward primer –5 CTTCCTAGGCTGGTCCTTACTGA 3
• Reverse primer - 5 CTGAGACCTGAAGAGCTAAAGAGCT 3
Primer Reconstitution
Primers are supplied in lyophilized form. Autoclaved distilled
water is used to prepare 100 × concentrations i.e. 10times the molecular
weight of primer is the volume of water required to prepare 100 ×
concentrations which is 100 µmolar solution.
• From this stock solution 10 × concentration is prepared as the
working solution for PCR.
POLYMERASECHAIN REACTION
Figure15,shows,the188bpMMP2genePCRproduct(lane2to8)on2%aga
rosegel.
Lane1 shows,100bpDNAladder-
markerfragmentsinclude1000,900,800,700,600,
500,400,300,200,100bp.
MASTERMIX:
• Genei Red Dye master mix in the following composition was
used.
• Master Mix consists of a unique inert red dye in addition to
basic components necessary for PCR.
• Reaction buffer consisted of Tris Hcl - 10mM at
pH 8.3
• KCl2 -50mM
• MgCl2 - 1.5mM acts as catalyst.
• dNTP’s were used in a concentration of 2.5 mM each.
• Taq polymerase in a concentration of 1.5 U.
• Primers were used in a concentration of 5 pmol and DNA was used in
a concentration of 200ng.
• PCR was done with a reaction volume of 25 µL with the following
components;
• PCR master mix – 12.5 µL
• Forward primer – 0.8 µL
• Reverse primer – 0.8 µL
• DNA – 2 .0µL
• Distilled water – 8.9 µL
• Total – 25 µL
• Amplification was carried out in an Applied Biosystems thermal
cycler with the following cycling conditions.
• Initial denaturation - 940 C -5min
• 37 cycles of
• Denaturation - 940C – 1 min
• Annealing - 60.50C – 1min
• Extension - 720C – 1min
• Final extension at 720C - 10 min.
• Amplified product – amplicons of 188 bp was identified by 2%
agarose gel electrophoresis by comparison with a known 100bp
DNA ladder. Figure 2.
AGAROSE GEL ELECTROPHORESIS
• PCR product is run on 2% agarose gel in a 30 mL agarose cast as
follows: 0.75g of agarose is weighed and dissolved in 30mL of TAE
buffer with a pH of 8.0.
• It is microwaved for 60 secs, cooled and 1.5 µL of ethidium bromide
(10mg/mL) is added. It is poured into a cast and allowed to solidify
for 15 min before it is kept in the electrophoresis tank.
• 8 µL of PCR product is loaded on to wells and 4 µL of 100bp DNA
ladder is loaded on to single well as a marker. It is electrophoresed
at 8V/cm for 45min and visualized under UV illumination.
RESTRICTION DIGESTION OF PCR PRODUCTS
MMP-2 polymorphism was determined by amplification by PCR
and digestion with the Bfa1 restriction enzyme (7.5 units for 4 hours)
followed by size fractionation in 3% Ethidium bromide –stained
Agarose Gel Electrophoresis.
Principle of Bfa1(Bacteroides fragilis) enzyme digestion
C allele does not have the restriction site hence will yield a 188 bp
fragment.
• T allele has the restriction site, hence gets cleaved to give 162 bp
and 26 bp fragments.
• Heterozygous individuals (CT) allele gets cleaved to give
188bp,162bp,and 26bp fragments.
FIG:16,RESTRICTION DIGESTION
PRODUCTS
Fig 16,shows,genotype analysis done on 2%agarose gel
electrophoresis using 100bp DNA ladder(lane1)
Lane8-Ladder
Lane(1,6)-TT
Lane(2,4,7)-CC,Lane(3,5)-CT
LIPID PROFILE
The biochemical parameters undertaken for the study were
determined using the following methodologies:
Estimation of Plasma Total Cholesterol
Method
Cholesterol Esterase – Cholesterol Oxidase
Kit used
Liquixx of ERBA diagnostics Manheim GmbH Ltd.
Principle
Cholesterol Esterase
Cholesterol Ester + H2O Cholesterol+ Fatty
acids
Cholesterol Oxidase
Cholesterol + O2 Cholestenone + H2O2
Peroxidase
2H2O2 + Phenol + 4- Aminoantipyrine Red quinine +
4H2O
 Intensity of the red complex is directly proportional to the
concentration of cholesterol which is measured at 505nm.
Reagents
Goods buffer (pH-6.4) 100mmol/L
Cholesterol Esterase ≥ 200U/L
Cholesterol Oxidase ≥ 100U/L
Peroxidase ≥ 3000 U/L
4- Aminoantipyrine 0.3 mmol/L
Phenol 5mmol/L
Standard (Cholesterol 200mg/dL)
Cholesterol 2g/L
Procedure
To 1 mL of the reconstituted reagent, 10 µL of plasma is added
and reading is taken after 5 mins of incubation at 37o C.
Reference Values
Cholesterol : 150-260 mg /dL
Estimation of Plasma Triglyceride
Method
 Enzymatic Colorimetric method
Kit Used
Liquixx of ERBA diagnostics Manheim GmbH Ltd.
Principle
Lipoprotein Lipase
Triglyceride + H2O Glycerol + Fatty acid
Glycerol Kinase
Glycerol + ATP Glycerol -3- Phosphate + ADP
Glycerol -3- Phosphate Oxidase
Glycerol -3- Phosphate Dihydroxy
acetone phosphate + H2O2
Peroxidase
H2O2 + 4 Aminoantipyrine+3,5-DHBS Red Quinone +2 H2O
The intensity of purple coloured complex formed during the
reaction is directly proportional to the triglyceride levels.
Reagents composition.
Pipes buffer (pH -7.0) 40mmol/L
Lipoprotein Lipase 4000U/L
 Glycerol Kinase 1500U/L
Glycerol -3- Phosphate Oxidase 4000 U/L
Peroxidase 2200 U/L
4- Aminoantipyrine 0.4 mmol/L
ATP 2 mmol/L
Magnesium 2.5mmol/L
DHBS(3,5-Dichloro -2 hydroxy 0.2mmol/L
Benzene sulphonate)
Standard (Triglycerides 200mg / dL)
Glycerol (Trig.Equivalent) 2g/L
Procedure
To 1 mL of the reconstituted reagent 10 µL of plasma is added
and read at 546nm after incubation at 37oC for 5mins.
Reference Range
Males 60- 165 mg/dL
Females 40- 140 mg/dL
Estimation of HDL Cholesterol
Method Modified polyvinyl sulphonic acid (PVS) and
polyethylene –glycol-methyl ether (PEGME)coupled classic
precipitation method.
Kit used Erba XL System Pack
Principle
LDL,VLDL and chylomicron (CM) react with PVS and PEGME
and the reaction results in inaccessibility of LDL,VLDL and chylomicron
(CM) by cholesterol oxidase (CHOD) and cholesterol esterase (CHER).
The enzymes selectively react with HDL to produce hydrogen peroxide
which, yields blue coloured complex upon oxidase condensation with
TODB (N , N –Bis ( 4 sulphonyl)-3 methylaniline)and 4-
aminoantipyrine (4-AA) in the presence of peroxidase (POD). The
intensity of chromogen (Quinone) formed during the reaction directly
is proportional to the HDL-C in the sample and is measured at
593nm.
PVS,PEGME
HDL +LDL+ VLDL + CM HDL+(LDL+VLDL+CM).
PVS/PEGME
CHER& CHOD
HDL-C + H2O +O2 4-cholestenone + Fatty acid + H2O2
Peroxidase
2H2O2 + TODB+ 4AA Blue colored complex + 2H2O
Reagents composition
Reagent 1
MES buffer pH 6.5 6.5mmol/L
TODB(N,N–Bis(4sulphonyl)-3methylaniline) 3mmol/L
polyvinyl sulphonic acid (PVS ) 50mg/L
polyethylene –glycol-methyl ether (PEGME) 30ml/L
Magnesium chloride (MgCl2) 2mmol
EDTA
Detergent
Reagent 2
MES buffer, pH – 6.5 50mmol/L
Cholesterol oxidase -20Ku/L
cholesterolesterase-5Ku/L
Peroxidase-5kU/L
4-Aminoantipyrine-0.9g/L
Detergent -0.5%
Calibrator
HDL-C 60mg/dL
Procedure
Reagent 1 & 2 are placed in the auto analyser with the following
assay parameters:
Assay type : 2 point
Primary wavelength nm : 600,
Secondary wavelength nm : 700
R-1 volume : 270,
R-2 volume : 70
Reaction direction : increasing,
Sample volume : 3 µL
Calibration : straight
Reference Values
Adult male : 35.3 – 79.5 mg /dL
Adultfemale : 42.0 – 88.0 mg / dL
Estimation of LDL Cholesterol.
Method Modified polyvinyl sulphonic acid (PVS) and polyethylene –
glycol-methyl ether (PEGME) coupled classic precipitation method.
Kit used
Erba XL System Packs
Principle
LDL,VLDL and chylomicron (CM) react with PVS and PEGME
and the reaction results in inaccessibility of LDL,VLDL and chylomicron
(CM) by cholesterol oxidase(CHOD) and cholesterol esterase (CHER),
whereas HDL reacts with the enzymes. Addition of reagent 2
containing a specific detergent releases LDL from the PVS/PEGME
complex. The released LDL reacts with the enzymes enzymes to
produce hydrogen peroxide which, yields blue coloured complex
upon oxidase condensation with TODB (N , N –Bis ( 4 sulphonyl)-3
methylaniline)and 4- aminoantipyrine (4-AA) in the presence of
peroxidase (POD). The intensity of chromogen (Quinone) formed
during the reaction directly is proportional to the HDL-C in the
sample and is measured at 593nm.
PVS,PEGME
HDL +LDL+ VLDL + CM HDL+(LDL+VLDL+CM).
PVS/PEGME
CHER& CHOD
HDL-C + H2O +O2 4-cholestenone+ Fatty acid + H2O2
(LDL+VLDL+CM).PVS/PEGME+Detergent LDL+(VLDL+CM).
PVS/PEGME .
CHER& CHOD
LDL+H2O+O2 Cholest-4en -3 –one+Fattyacid+H2O2.
Peroxidase
2H2O2+4AA+TODB Quinone+5H2O
Reagents composition
Reagent 1
MES buffer pH 6.5 50mmol/L
polyvinyl sulphonic acid (PVS ) 50mg/L
polyethylene –glycol-methyl ether (PEGME) 30ml/L
Magnesium chloride (MgCl2) 2mmol
EDTA
Detergent
TODB (N,N-Bis(4-sulfobutyl)-3-methylaniline) 3mmol
Reagent 2
MES buffer pH 6.5 50mmol/L
EDTA
Detergent
TODB(N , N –Bis ( 4 sulphonyl)-3 methylaniline) 3mmol/L
Calibrator
LDL-C 107mg/dL
Procedure
Reagent 1 & 2 are placed in the auto analyser with the
following assay
parameters:
Assay type : 2 point
Primary wavelength nm : 600,
Secondary wavelength nm : 700
R-1 volume : 210,
R-2 volume : 70
Reaction direction : increasing,
Sample volume : 3 µL
Calibration : straight
Expected values
Optimal <100mg/Dl
Near/above optimal - 100-129mg/dL
Boder line high - 130-159mg/dL
High -160-189mg/dL
Very high -189mg/dL
VLDL Cholesterol
This parameter was calculated by using formula given below:
VLDL-C = TGL/5
Estimation of Plasma MMP-2 activity
MMP-2 activity in plasma was measured by ELISA
Principle
Heparinised plasma is used for measurement MMP-2 concentration
by ELISA. The kit contains 96 – wells plate. Wells are coated with anti-
human MMP-2 antibody . MMP-2 present in a sample is bound to the
wells by immobilized antibody.Then biotinylated anti-human MMP-2
antibodyis added. After washing away unbound biotinylated antibody ,
add HRP-conjugated streptavidin to the wells is added. The wells are
again washed ,and TMB substrate solution is added and color
develops in proportion to the amount of MMP-2 bound. The color
changes from blue to yellow by the addition of stop solution and the
intensity of the color is read at 450nm.
Reagents
1. MMP-2 Microplate coated with anti –human MMP-2.
2. Wash Buffer Concentrate.
3. Standards: Recombinant human MMP-2.
4. Assay Diluent: For Standard/Sample dilution.
5. Detection Antibody MMP-2: Biotinylated anti-human MMP-2.
6. HRP- Streptavidin Concentrate.
7. TMB One- Step Substrate Reagent.
8. Stop Solution.
Assay Procedure
Prepare all reagents samples, controls, and standards and bring
them to room temperature before use.
1. Add 100µl standards ,samples and controls to each well. Incubate
2 hours at room temperature . Discard and wash.
2. Add 100 µl prepared biotin antibody to each well. Incubate 1
hour at room temperature. Discard the solution and wash each
well with wash buffer.
3. Add 100 µl prepared HRP- Streptovidin solution. Incubate 45
minutes at room temperature. . Discard the solution and wash
each well with wash buffer.
4. . Add 100 µl TMB One-Step Substrate Reagent to each well.
Incubate 30 minutes at room temperature.
5. Add 50 µl Stop Solution to each well. Read at 450nm
immediately.
CALCULATION
Calculate the mean absorbance for each set of standards,
samples and controls and substract the average zero standard optical
density. Plot the standard curve on log-log graph paper with standard
concentration on the x –axis and absorbance on the y-axis and draw
the best-fit straight line through the standard points.
 
Statistical Analysis 
STATISTICAL ANALYSIS
1. Allele frequencies were calculated by allele counting.
2. Age , BMI, serum lipid levels were compared between control
subjects and cases by students t test.
3. Genotype frequency distribution between cases and controls were
compared with a χ2 test .
4. MMP-2 activity was compared between control and cases by
Student t test p<0.05 was considered significant.
5. MMP-2 activity for both cases and controls was entered into a
Microsoft Excel Spread Sheet. MMP-2 activity is compared
between MMP-2 genotypes by using students t test.
6. Logistic regression analysis was performed to evaluate the
interaction between human MMP-2 genotypes and other variables
in relation to the prevalence of Myocardial Infarction. Independent
variables included in the analysis were age (quantitative ), sex
(male/female),smoking(yes/no),Alcoholism(Yes/No),
Hypertension (Yes/No), Diabetes (Yes/No), Serum Levels of
Cholesterol , Triglycerides (Quantitative).
Results 
MASTER CHART
Table-1: LIPID LEVELS, BMI AND GENOTYPE OF CASES
Sl No
AGE SEX Angio DM HYT SMK ALC WT HT BMI CHOL TGL HDL LDL MMP-2 MMP-2
1 48 M SVD NO YES YES YES 66 1.57 26.78
159 194.7 26.8 
92.3 747 CC
2 56 M SVD NO NO NO YES 71 1.64 26.48
175.3 180.5 44.8 89.3 756 
CC
3 49 F SVD NO NO NO NO 63 1.57 25.68
175.7 175.6 44.7 90.4 816 
CC
4 60 M SVD NO YES YES YES 68 1.62 25.89
167.9 116.9 50.1 91.9 550 
CT
5 53 M SVD YES NO NO NO 59 1.52 25.77
196.7 194.5 24.4 90.4 534 
CC
6 58 M SVD NO NO YES NO 78 1.68 27.67
197.6 197.8 23.5 129.4 921 
CC
7 57 M SVD NO YES YES YES 58 1.64 21.67
174.7 96.8 59.4 130.5 782 
CC
8 50 M SVD NO NO YES YES 72 1.71 24.78
188.5 185.7 22.8 91.9 712 
CC
9 55 F TVD YES NO NO NO 74 1.57 29.98
214 195.7 40.4 124.6 823 
CC
10 61 M TVD YES YES NO NO 81 1.59 31.99
161.8 180.8 44.1 130.5 535 
CT
11 47 M SVD NO NO YES NO 58 1.64 21.57
158.8 184.8 40.3 77.5 861 
CC
12 63 F SVD YES NO NO NO 64 1.7 21.99
215.5 193.6 38.3 77.5 956 
CC
13 55 M SVD YES YES YES YES 71 1.62 26.87
210.2 198.9 31.9 134.5 400 
TT
14 56 M SVD YES YES YES YES 61 1.7 21.24
146.2 88.8 
47
134.5 842 
CC
15 58 M SVD NO NO NO YES 56 1.61 21.78
207.7 182.5 43 84.9 922 
CC
16 57 M TVD NO NO YES NO 80 1.58 32.01
203.7 196.9 44.8 130.4 953 
CC
17 48 M DVD NO NO YES NO 62 1.69 21.78
160.5 188.4 44.7 130.4 
717 CC
18 62 M SVD YES YES NO NO 71 1.54 29.87
150.4 98.5 50.1 80.3 413 
TT
19 54 F SVD NO YES NO NO 57 1.64 21.24
176.9 98.4 24.4 80.2 545 
CC
20 48 M DVD NO NO YES NO 59 1.72 20.01
209.8 189.4 26.8 95.8 405 
TT
21 49 M DVD YES YES YES NO 79 1.71 27.02
168.1 106.5 59.4 130.5 782 
CC
22 47 F TVD NO NO NO NO 54 1.53 22.87
168.7 188.4 22.8 90.2 532 
CT
23 59 F SVD YES YES NO NO 83 1.64 30.88
174.6 196.9 40.4 90.1 832 
CC
24 55 M SVD NO NO YES YES 60 1.63 22.66
176.6 189.5 44.1 95.8 817 
CC
25 54 M DVD NO YES NO NO 62 1.61 23.98
179.7 87.3 40.3 100.5 523 
CT
26 52 M TVD YES NO YES YES 72 1.71 24.56
160.3 197.8 38.3 94.5 727 
CC
27 60 M DVD NO NO YES YES 69 1.67 24.78
206.3 80.6 31.9 90.2 754 
CC
28 55 F DVD YES YES NO NO 61 1.6 23.67
216.4 185.7 39.5 132.8 876 
CC
29 52 M TVD YES NO YES NO 69 1.71 23.68
172.2 90.2 36.8 129.5 417 
CC
30 65 M DVD NO YES NO NO 70 1.65 25.77
170.3 84.6 29.9 94.5 515 
CT
31 56 M TVD NO YES YES YES 75 1.58 29.99
175.3 196.4 38.5 92.4 789 
CC
32 49 F DVD YES NO NO NO 73 1.62 27.68
162.2 186.7 46.4 100.3 987 
CC
33 57 M SVD NO NO NO NO 58 1.6 22.79
199.4 193.5 57.4 82.8 403 
TT
34 53 M SVD NO NO YES YES 61 1.58 24.57
184.8 83.6 37.4 124.9 747 
CC
35 57 M TVD NO YES NO YES 84 1.71 28.67
201.4 188.4 52.6 106.3 859 
CC
36 56 M TVD NO NO YES YES 76 1.75 24.67
175.9 197.8 36.7 129.5 408 
TT
37 61 M DVD YES NO NO NO 64 1.64 23.68
201.9 84.8 35.4 95.7 822 
CC
38 56 M SVD YES YES YES NO 55 1.6 21.55
213.9 184.6 34.2 109.6 510 
CT
39 48 M TVD NO NO YES YES 77 1.62 29.46
206.8 179.6 63.7 134.7 867 
CC
40 59 M SVD NO YES NO NO 60 1.57 24.47
205.2 190.8 26.5 132.8 921 
CC
41 61 M DVD NO YES YES YES 60 1.66 21.79
152.5 195.9 
27
137.4 942 
CC
42 51 M TVD NO NO YES YES 67 1.61 25.89
166.5 78.5 31.8 80.9 765 
CC
43 50 M SVD YES YES NO NO 69 1.64 25.66
200.6 189.7 24.6 94.5 516 
CC
44 55 M DVD NO YES YES YES 71 1.63 26.89
178.8 130.6 51.9 120.3 511 
CT
45 57 M SVD NO NO YES YES 67 1.67 23.99
156.1 188.9 31.1 102.4 678 
CC
46 49 M SVD NO N0 YES YES 68 1.59 26.79
211.2 96.8 49.2 82.8 987 
CC
 
47 54 M SVD NO NO NO NO 62 1.55 25.87
183.6 135.8 34.6 142.1 504 
CC
 
48 60 F SVD NO YES NO NO 60 1.56 24.57
249.4 188.3 49.9 116.3 765 
CC
 
49 53 M SVD NO YES YES YES 76 1.6 29.68
169.3 184.6 37.9 153.8 400 
TT
 
50 59 M SVD YES NO YES YES 66 1.67 23.55
194.6 184.7 25.6 105.7 529 
CT
 
51 50 M SVD YES NO YES NO 73 1.72 24.57
194.6 186.9 54.7 106.9 876 
CC
 
52 57 M DVD YES NO YES YES 57 1.63 21.46
209.6 195.4 22.7 134.7 854 
CC
 
53 52 M SVD NO NO YES NO 68 1.65 24.88
211.2 193.7 46.3 115.8 
652 CC
 
54 54 M SVD NO YES YES YES 74 1.67 26.43
169.3 74.7 31.8 100.3 
712 CC
 
55 49 M DVD NO NO NO NO 63 1.63 23.54
208.1 185.7 52.7 
98.5
759 
CC
 
56 58 M DVD NO YES YES YES 79 1.69 27.71
151.8 
154.7
50.1 143.6 720 
CC
 
58 53 F DVD NO YES NO NO 68 1.62 25.81
179.2 164.6 29.6 92.5 875 
CC
 
57 47 F SVD YES NO NO NO 62 1.66 22.54
150.7 189.4 39.2 100.2 852 
CC
 
59 49 M DVD YES YES NO NO 73 1.74 24.21
168.9 189.7 38.9 80.9 489 
CC
 
60 54 M DVD N0 NO NO NO 81 1.64 29.98
241.9 184.8 48.1 84.2 786 
CC
 
61 62 M TVD YES NO NO NO 76 1.69 26.53
191.5 74.7 43.1 159.4 389 
CC
 
62 48 M TVD YES YES NO NO 73 1.72 24.72
167.8 194.6 59.1 120.3 542 
CT
 
63 53 M TVD YES NO YES YES 72 1.65 26 .54
208.7 190.7 31.1 92.4 865 
CC
 
64 52 M TVD No NO YES YES 78 1.71 26.84
167.7 89.6 33.4 133.9 879 
CC
 
65 49 M TVD NO NO NO NO 56 1.58 22.34
217.2 190.4 39.9 88.6 530 
CT
 
66 51 M DVD NO NO YES YES 74 1.67 26.65
172.8 184.3 60.1 142.1 786 
CC
 
67 48 M DVD NO YES NO NO 73 1.65 26.88
161.7 190.5 32.9 93.4 432 
CC
 
68 60 M DVD NO YES YES YES 68 1.57 27.74
209.9 83.9 38.7 89.3 400 
TT
 
69 59 F SVD N NO NO NO 73 1.57 29.71
222.2 196.8 
48.2
132.6 723 
CC
 
70 62 M DVD NO NO YES YES 72 1.67 25.82
171.6 196.9 
47.5
153.8 874 
CC
 
71 57 M TVD NO NO NO NO 80 1.64 29.81
183.4 177.5 49.1 94.6 543 
CT
 
72 59 M DVD YES YES NO NO 57 1.68 20.24
209.3 154 35.2 116.9 823 
CC
 
73 58 M SVD NO NO YES YES 80 1.68 28.53
208.5 197.6 24.6 130.1 789 
CC
 
74 60 F DVD NO YES NO NO 73 1.66 26.41
185.3 189.7 34.9 129.7 795 
CC
 
75 52 M DVD NO YES NO NO 57 1.63 21.58
189.3 151.4 23.9 110.4 789 
CC
 
76 61 M TVD NO YES YES YES 78 1.65 28.75
166.3 192.4 40.1 93.5 806 
CC
77 51 M SVD NO YES YES YES 75 1.64 28.02
212 198.9 38.7 92.8 531 
CC
78 55 M SVD YES NO NO NO 64 1.65 23.53
169.42 172.5 31.3 154.8 765 
CC
79 54 M DVD NO YES NO NO 69 1.67 24.65
253.2 175.3 58.7 112.5 550 
CT
80 50 M TVD YES YES YES YES 82 1.66 29.83
185.9 164.6 39.7 54.8 890 
CC
81 62 M DVD YES NO NO NO 74 1.6 28.93
136.3 196.4 56.5 89.3 432 
CC
82 55 M TVD YES YES YES YES 73 1.62 27.72 143 111.9 31.5 132.7 541 CT
28 49 F SVD YES YES NO NO 78 1.62 29.83 212 141.6 40.5 131.4 765 CC
84 48 M DVD NO NO NO NO 76 1.65 27.81 219.9 80.6 34.8 143.6 962 CC
85 57 M SVD NO YES YES YES 74 1.64 27.51 156.9 180.5 36.4 100.2 413 TT
86 54 M SVD NO YES YES NO 73 1.71 24.92 168.7 88.4 34.2 89.4 942 CC
87 58 M TVD NO YES NO NO 57 1.66 20.61 231.7 187.8 34.8 159.4 535 CT
88 53 M SVD NO NO YES YES 75 1.64 27.9 202.6 96.9 37.2 125.9 426 CC
89 60 M SVD NO NO YES YES 80 1.65 29.51 123.5 185.3 31.4 62.9 805 CC
90 49 M DVD NO NO YES YES 55 1.63 20.71 169.4 189.8 34.6 90.3 467 CC
91 55 M TVD NO NO YES YES 73 1.63 27.61 138.4 154.7 39.8 56.3 890 CC
92 52 M SVD YES YES YES YES 78 1.62 29.84 164.2 74.8 35.7 87.9 532 CT
93 53 M SVD NO NO YES YES 52 1.55 21.51 212.7 191.2 38.7 135.8 621 CC
94 52 M TVD NO NO YES YES 57 1.54 23.96 226.3 183.7 36.8 145.9 764 CC
95 49 M SVD YES NO YES YES 62 1.65 22.65 167.1 96.3 42.1 92.4 874 CC
96 62 F SVD YES NO NO NO 82 1.66 29.72 160.5 190.5 36.9 90.5 671 CC
97 55 M TVD NO YES NO NO 69 1.64 25.83 169.7 199.2 32.8 88.6 715 CC
98 57 M SVD NO YES YES YES 66 1.69 22.94 151.7 190.7 36.2 64.7 540 CT
99 60 M SVD YES YES NO NO 70 1.62 26.83
153.9 193.2 
41.1
80.49 
835 CC
100 51 M SVD NO NO NO NO 82 1.66 29.83
192.2 175.4 
37.2
123.4 
921 CC
S.NO 
Age 
(yrs) 
Sex 
Angio 
Finding 
DM HYT SMK ALC WT(kg) HT(m) 
BMI 
(kg/m) 
CHOL 
(mg/dL) 
TGL 
(mg/dL) 
HDL 
(mg/dL) 
LDL 
(mg/dL) 
MMP2 
Activity(ng/ml) 
MMP2 
Genotype 
1 54 M NA NO YES NO NO 64 1.62 24.46 126.78 102.4 45.3 57.2 550 CC 
2 52 M NA NO NO YES NO 62 1.68 21.89 176.12 144.6 29.6 50.8 432 CT 
3 51 M NA YES NO YES NO 66 1.63 24.8 171.28 133.4 46.9 56.9 515 CC 
4 49 F NA NO YES NO NO 70 1.72 23.68 172.72 153.6 43.8 52.3 367 CC 
5 47 M NA NO NO NO YES 72 1.67 25.67 159.16 145.8 44.8 58.9 389 CT 
6 60 M NA NO NO YES YES 64 1.72 21.57 173.96 157.8 47.5 54.5 534 CC 
7 58 M NA YES NO YES NO 74 1.72 24.89 150.66 146.8 37.5 101.9 542 CC 
8 54 M NA YES NO NO YES 63 1.67 22.46 134.86 156.8 29.5 109.5 421 CT 
9 49 M NA NO YES YES YES 69 1.63 25.86 158.52 152.6 58.4 45.7 649 CC 
10 49 M NA NO YES YES NO 74 1.66 26.9 170.74 159.7 43.7 53.8 402 TT 
11 51 F NA YES NO NO NO 70 1.64 25.9 126.8 153.5 28.6 102.5 519 CC 
12 54 M NA NO YES NO YES 59 1.58 23.68 141.68 100.4 30.5 103.2 487 CT 
13 59 M NA NO NO NO YES 76 1.64 28.14 166.04 103.2 37.8 51.1 545 CC 
14 56 M NA YES NO YES YES 67 1.69 23.44 165.76 120.3 59.7 57.8 406 TT 
15 53 M NA YES NO YES NO 80 1.61 30.89 181.66 144.3 36.8 112.4 615 CC 
16 59 M NA NO YES NO YES 79 1.7 27.21 175.46 156.8 37.8 103.9 421 CT 
17 54 M NA NO YES YES NO 58 1.68 20.57 156.6 135.4 39.9 106.9 511 CC 
18 56 M NA NO YES NO YES 65 1.63 24.6 181.04 90.7 32.4 58.9 532 CC 
19 55 M NA NO NO YES YES 66 1.6 25.79 168.8 153.5 26.8 67.3 433 CT 
20 60 F NA YES NO NO NO 70 1.71 23.91 171.44 155.7 53.5 55.3 567 CC 
21 54 M NA YES NO YES YES 68 1.7 23.47 170.04 108.7 37.6 100.4 462 CC 
22 57 M NA YES NO NO YES 69 1.67 24.86 152.18 148.4 34.5 59.4 453 CT 
23 58 M NA NO YES YES NO 65 1.72 21.91 117.9 124.5 37.9 52.9 740 CC 
24 55 M NA NO NO NO YES 64 1.71 21.87 180.74 115.7 59.1 114.7 491 CC 
25 59 M NA NO YES NO NO 71 1.73 23.6 166.32 102.5 36.1 100.1 482 CT 
26 60 F NA NO NO NO NO 60 1.66 21.67 174.12 98.5 38.9 104.3 473 CC 
27 61 M NA YES NO YES YES 63 1.69 21.97 184.88 125.6 37.3 99.3 400 TT 
28 60 M NA YES NO NO YES 74 1.63 27.89 129.6 141.6 59.5 104.9 476 CC 
29 54 M NA NO YES YES YES 69 1.73 22.96 130.12 158.9 37.8 103.6 453 CT 
30 51 M NA NO YES YES YES 70 1.66 25.26 128.02 116.5 36.9 104.9 432 CC 
31 53 F NA NO NO NO NO 72 1.65 26.49 153.5 132.6 49 114.6 465 CC 
32 56 M NA YES NO YES YES 74 1.69 25.79 179.9 153.6 47.9 54.4 485 CC 
33 59 M NA NO YES NO NO 73 1.65 26.68 179.14 121.5 40.9 58.7 687 CT 
34 57 M NA YES NO YES YES 81 1.61 31.14 160.88 82.5 39.9 53.4 510 CC 
35 62 M NA YES NO YES YES 69 1.7 23.94 170.66 163.7 40.8 84.4 543 TT 
36 57 M NA NO YES YES NO 60 1.72 20.35 185.94 91.9 53.6 105.8 517 CC 
37 55 M NA NO YES NO YES 73 1.59 28.97 133.4 127.8 36.8 105.6 508 CT 
38 49 M NA NO NO YES YES 80 1.59 31.78 193.36 100.7 40.6 97.9 542 CC 
39 48 M NA NO YES NO NO 79 1.62 29.95 182.02 92.5 34.6 106.5 403 TT 
40 50 M NA YES NO NO YES 75 1.71 25.69 166.12 87.8 53.1 108.7 567 CC 
41 55 M NA YES NO YES YES 75 1.74 24.68 133.78 134.6 56.8 54.1 563 CC 
42 56 M NA NO YES NO YES 81 1.64 30.04 142.68 98.6 64.3 107 480 CT 
43 59 M NA NO YES YES NO 79 1.67 28.3 172.14 107.9 44.6 106 523 CC 
44 51 M NA YES NO YES NO 78 1.7 27.11 132.32 91.4 52.3 90.1 400 TT 
45 58 M NA NO YES NO YES 59 1.68 20.91 190.56 143.7 53.6 54.6 510 CC 
46 52 F NA NO NO NO NO 68 1.7 23.37 168.92 144.6 61.8 58.6 506 CT 
47 57 M NA NO YES YES YES 70 1.68 24.68 127.1 156.8 40.6 98.8 531 CC 
48 53 M NA YES NO NO NO 71 1.66 25.79 175.98 132.6 44.9 54.5 548 CC 
49 56 M NA NO YES YES NO 79 1.58 31.68 135.22 100.5 37.6 117.6 387 CT 
50 54 M NA NO NO NO NO 61 1.67 21.89 139.12 125.4 41.8 96.6 375 CC 
51 55 M NA YES NO YES YES 59 1.72 20.04 126.08 113.6 54.4 48.6 354 TT 
52 56 M NA YES NO YES NO 68 1.69 23.78 172.92 98.6 56.5 90.4 742 CC 
53 54 M NA YES NO NO YES 70 1.61 26.79 181.7 90.4 57.6 50.9 321 CT 
54 49 M NA YES NO YES NO 72 1.72 24.47 131.58 143.6 58.6 56.8 362 CC 
55 48 F NA NO YES NO NO 78 1.64 28.91 177.12 142.8 51.8 52.2 305 TT 
56 53 M NA NO NO YES NO 71 1.69 24.78 144.42 143.6 39.8 100.4 520 CC 
57 57 M NA YES NO YES YES 79 1.62 30.13 123.56 94.5 59.4 112.4 532 CC 
58 52 M NA YES NO NO NO 66 1.69 23.17 169.58 169.9 39.9 50.4 433 CT 
59 59 M NA NO YES YES YES 59 1.66 21.47 167.52 132.6 56.3 58.9 532 CC 
60 51 M NA NO NO NO NO 58 1.62 21.97 182.62 154.6 47.9 106.9 543 CC 
61 59 M NA YES NO NO YES 70 1.68 24.87 140.64 107.8 40.9 104.3 418 CT 
62 61 F NA YES NO NO NO 72 1.69 25.11 209.94 109.4 39.9 109.4 510 CC 
63 48 M NA NO YES NO YES 74 1.68 26.34 146.3 102.6 40.8 53.3 526 CC 
64 55 M NA NO NO YES YES 60 1.65 21.98 124.6 140.6 53.6 115.4 655 CT 
65 56 M NA YES NO NO NO 80 1.58 31.98 191.04 154.7 36.8 65.4 421 CC 
66 52 M NA NO YES YES YES 59 1.67 21.2 162.04 155.7 40.6 55.4 477 CT 
67 58 M NA NO NO NO NO 64 1.61 24.54 158.42 143.5 34.6 118.6 553 CC 
68 56 F NA YES NO NO NO 65 1.65 23.87 183.5 117 53.1 95.9 589 CC 
69 54 M NA YES NO YES YES 66 1.67 23.67 184.02 145.7 56.8 105 415 CT 
70 51 M NA NO YES YES NO 59 1.67 21.23 155.94 103.6 64.3 109 710 CC 
71 49 M NA NO NO NO YES 59 1.72 20.01 181.34 81.5 44.6 74 547 CC 
72 58 M NA YES NO YES NO 60 1.72 20.23 187.5 152.6 52.3 108 400 CT 
73 57 F NA NO YES NO NO 63 1.71 21.56 147.34 94.7 53.6 56.4 487 CC 
74 60 M NA YES NO YES NO 57 1.61 21.89 139.64 156.7 61.8 49.8 322 CT 
75 53 F NA YES NO NO NO 72 1.67 25.67 144.06 142.5 40.6 73.8 512 CC 
76 52 M NA NO NO YES YES 62 1.72 20.87 185.14 145.7 44.9 119 432 CT 
77 48 M NA NO YES NO NO 73 1.69 25.64 169.72 144.7 37.6 100.5 543 CC 
78 60 M NA YES NO YES YES 79 1.68 27.98 127.4 86.8 41.8 50.4 387 TT 
79 56 M NA NO NO YES NO 75 1.73 24.98 168.34 159.7 54.4 94.3 546 CC 
80 59 M NA YES NO YES NO 78 1.71 26.97 122.62 155.6 56.5 49.9 390 CT 
81 51 F NA NO YES NO NO 79 1.65 28.99 185.08 80.5 57.6 102 521 CC 
82 58 M NA YES NO NO NO 76 1.61 29.21 137.5 130.7 58.6 56.8 456 CT 
83 52 M NA YES YES YES YES 69 1.68 24.54 181.88 133.5 51.8 100.9 512 CC 
84 57 M NA NO NO YES NO 77 1.64 28.75 184.54 130.7 39.8 114 377 CT 
85 53 M NA NO NO NO NO 62 1.68 21.99 143.36 142.6 59.4 112 365 CC 
86 56 M NA YES NO NO NO 65 1.73 21.54 151.82 88.9 39.9 53 325 CC 
87 55 F NA YES NO NO NO 60 1.71 20.6 139.36 157.5 56.3 50.4 375 CT 
88 54 M NA NO YES NO NO 61 1.69 21.4 156.38 150.4 48 58.9 538 CC 
89 49 M NA NO YES NO NO 78 1.67 27.88 140.9 165.7 47.9 106.9 326 CT 
90 44 M NA YES NO YES NO 77 1.62 29.31 131.55 96.8 40.9 104.3 525 CC 
91 60 M NA NO YES YES NO 79 1.61 30.54 172.24 150.6 39.9 109.4 401 TT 
92 54 M NA NO NO NO NO 69 1.68 24.56 175.24 84.8 40.8 53.3 525 CC 
93 48 M NA YES NO YES NO 68 1.68 23.99 145.72 90.4 53.6 115.4 401 CT 
94 61 M NA NO YES NO YES 66 1.64 24.57 191.5 92.5 36.8 65.4 461 CC 
95 48 M NA YES NO YES YES 65 1.73 21.79 136.68 157.7 40.6 55.4 300 CC 
96 54 M NA YES NO NO NO 60 1.62 22.76 142.44 114.7 34.6 118.6 500 CT 
97 58 M NA NO YES NO NO 71 1.73 23.67 135.02 149.7 53.1 95.9 543 CC 
98 57 M NA NO NO YES NO 69 1.66 24.98 126.52 142.6 56.8 105 526 CC 
99 59 F NA YES NO NO NO 74 1.66 26.78 137 150.5 64.3 109 523 CC 
100 54 F NA YES NO NO NO 76 1.65 27.87 139 150.4 44.6 74 402 TT 

TABLE3: CHARACTERISTICS OF PATIENTS WITH MI AND OF
CONTROL SUBJECTS
Variables Case Control P value
Age 55.0±8.8 55.0±7.6 0.273 –NS
Sex Male 85(85%) 85 (85%) 0.495 –NS
Female 15 (15%) 15 (15%) 0.495-NS
DM 34 (34%) 44(44%) 0.094–NS
HT 45(45%) 35 (35%) 0.149 –NS
SMK 54(54%) 48(48%) 0.991 -NS
ALC 46(46%) 42(42%) 0.565-NS
BMI 25.69±0.57 24.91±5.80 0.638-NS
CHOLESTEROL 184.73±5.05 158.47±4.25 0.001-S
TRIGLYCERIDES 162.01±8.40 128.45±5.04 0.001-S
HIGH DENSITY
LIPOPROTEIN
39.21±1.90 45.98±1.84 0.004-S
LOW DENSITY
LIPOPROTEIN
108.25±4.77 83.29±4.97 0.001-S
Fig17,GENOTYPE DISTRIBUTION OF MMP-2 GENE
Table4,GENOTYPE DISTRIBUTION OF MMP-2 GENE
Type
Total
P Value
Cases control
MMP2_Genotype CC Count 76 59 135
% within
MMP2_Ge
notype
56.3% 43.7% 100.0%
Chi – sq. =
6.87
P = 0.032
CT Count 16 30 46
% within
MMP2_Ge
notype
34.8% 65.2% 100.0%
TT Count 8 11 19
% within
MMP2_Ge
notype
42.1% 57.9% 100.0%
Total Count 100 100 200
% within
MMP2_Ge
notype
50.0% 50.0% 100.0%
TABLE5: COMPARISON OF MMP-2 ACTIVITY AMONG CASES
AND CONTROLS
Variable Case Control P value
ACTIVITY (ng/mL) 698.02 +178.05 481.35 +90.45 0.001 –S
Fig18 ,COMPARISON OF MMP
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TABLE 6: RELATIONSHIP BETWEEN MMP-2 ACTIVITY AND
GENOTYPE
Genotype MMP-2 Activity(ng/ml) P Value
CC 655±174 .0001-S
CT 472±78 .0001-S
TT 402±42 .0001-S
Fig 19, RELATIONSHIP BETWEEN MMP
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TABLE-7:MULTIPLE LOGISTIC REGRESSION ANALYSIS
Variables B S.E WALD df sig Exp(B
)
UPPER LOWER
95%
AGE .081 .074 1.204 1 .273 1.084 .938 1.252
SEX -.848 1.242 .466 1 .495 .428 .038 4.884
SMOKING -.009 .776 .000 1 .991 .991 .217 4.538
ALCOHOLISM -.402 .699 .331 1 .565 .669 .170 2.634
DIABETES -1.246 .745 2.796 1 .094 .288 .067 1.239
BMI .823 1.748 .222 1 .638 2.277 .074 70.002
TOTALCHOLES
TEROL
.059 .017 11.948 1 .001 1.061 1.026 1.097
TRIGLYCERID
ES
.041 .010 15.047 1 .000 1.041 1.020 1.063
HDL -.105 .037 8.164 1 .004 .900 .838 .968
a. The reference category is: Control
LDL .062 .017 12.589 1 .000 1.064 1.028 1.101
MMP-2
ACTIVIT
Y
.015 .003 21.993 1 .000 1.015 1.009 1.022
MMP-2
POLYMORPHIS
M CC
-.782 1.006 .604 1 .007 1.958 0.664 3.289
MMP-2
POLYMORPHIS
M CT
-.640 .986 .421 1 .009 1.527 0.576 3.543
INTERCEPT -.625 92.567 .132 1 .716
RESULTS
• Table 3 shows Age , Sex , BMI , High Density Lipoprotein
levels and conventional risk factor distribution among cases and
control subjects. We obtained a nonsignificant p value with respect to
all the confounding variables like age, sex, BMI, history of diabetes,
hypertension, smoking, alcoholism. There was a significant difference in
Total cholesterol level (high in cases 184.73±5.05), low in controls
158.47±4.25), Triglycerides level (high in cases 162.01±8.40),low in
controls128.45±5.04), High Density Lipoprotein level ( low in cases
39.21 +1.90),high in controls 45.98±1.84), Low Density Lipoprotein
level (high in cases 108.25±4.77), low in controls (83.29±4.97).
• Table 4 shows Genotype distribution of human matrix metallo
proteinase-2 gene in patients with MI and control subjects.
• Table 4 shows CC genotype was more frequent among cases
(76%) when compared to controls (59%) . In contrast TT was more
common among controls (11%) when compared to cases(8%).
Distribution of CT genotype also between cases (16%) and controls
(30%). P value is 0.032. The Allele frequencies were CC=135, CT=46,
TT=19. This was found to be in Hardy Weinberg equilibrium.
• Table 5 shows the comparison of Matrix Metalloproteinase-2
activity among cases and controls. Significantly high MMP-2 activity
could be observed among cases (698+178) when compared to controls.
(481 + 90).Pvalue <0.001.
• Table 6 shows the difference in MMP-2 activity between CC,CT
genotype and TT genotype. The activity was significantly higher
among CC genotype individuals (655±174) when compared to CT(472+
78) and TT (402 ± 42) genotype individuals . Pvalue <0.001.
• Table 7 shows,Multiple logistic regression analysis. After
correction of all confounding variables CC genotype remains significant
between cases and controls.
Discussion 
DISCUSSION
Genetic factors and various environmental factors are
involved in a combination with development of MI. The susceptibility
to MI is a complex trait162 . This study was conducted to determine
the association of MMP-2 polymorphism and its related MMP-2
activity with Myocardial Infarction. The three human MMP-2
genotypes and phenotypes were determined in 100 patients with MI
confirmed by angiography and 100 control subjects.
The insignificant p value with respect to all the confounding
variables like age ,sex, BMI, history of diabetes, hypertension ,smoking,
alcoholism, showed that the cases and controls groups had been
perfectly matched.The plasma MMP-2 levels are increased in cases
when compared to controls. The significantly high MMP-2 levels in
cases(698±178) ,controls(481±90)P(<0.001) re-emphasizes the fact that
causes atherogenesis and plaque rupture.
When genotype analysis was performed , distribution of CC
genotype was significantly higher among cases (76%) when compared
to controls (59%). Pvalue was 0.032 showing that is significant. This
indicates that CC genotype is an independent risk factor for
atherosclerotic plaque rupture.The evidence available showed that
there is a significantly high MMP-2 activity among cases (698±178)
when compared to controls (481±90). P value was less than 0.001. This
shows that high MMP-2 activity is an independent risk factor for
atherosclerosis.
When MMP-2 activity compared between MMP-2 genotypes
there was a significantly high MMP-2 activity among CC genotypic
individuals (655±174).and CT genotypic individuals (472±78), when
compared to TT genotypic individuals (402±42). P value was (<0.001),
suggesting the fact that CC genotype is associated with high activity
and this high activity makes a person more susceptible to
atherosclerosis. Hence CC genotype and the resultant high MMP-2
activity can be considered as an independent risk factor for
atherosclerotic plaque rupture.
On multiple logistic regression analysis, CC genotype will increase the
susceptibility of atherosclerosis. The odds ratio on multiple logistic
regression analysis was 1.95 i.e., a person with CC genotype is 1.95
times at a risk for atherosclerosis after all the confounding variables are
matched
Conclusion 
CONCLUSION
• The high plasma MMP-2 activity and the CC genotype may be
independent risk factors for Myocardial Infarction.
• MMP-2 activity can be used as a parameter for assessing
Myocardial Infarction risk .
• MMP-2 activity can also be used to assess the outcome of
atherosclerotic plaque rupture.
Future Prospects of the 
Study 
SCOPEFOR FURTHER STUDY
• Research aimed at identifying the strategies to inhibit Matrix
Metallo Proteinase-2 activity can be supported.
• Other Matrix Metallo Proteinase-2 gene polymorphisms may be
explored to highlight their association with Matrix
MetalloProteinase-2 activity and atherosclerosis and plaque
rupture.
• Various transcriptional factors modulating the Matrix Metallo
Proteinase-2 gene expression can be studied.
• MMP-2 inhibitors and TIMP-2 therapy can be tried in all those
who have higher MMP-2 gene expression. But since
atherosclerosis is a multifactorial disease, it does not look
promising.
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ANNEXURES 


PATIENTCONSENT FORM
Title of the study : “ASSOCIATION OF MATRIX METALLOPROTEINASE-
2 GENE PROMOTER POLYMORPHISM WITH MYOCARDIAL
INFARCTION. ”
Name : Date :
Age : OP No :
Sex : Project Patient No :
The details of the study have been provided to me in writing
and explained to me in my own language.
I confirm that I have understood the above study and had the
opportunity to ask questions.
I understand that my participation in the study is voluntary
and that I am free to withdraw at any time, without giving any
reason, without the medical care that will normally be provided by
the hospital being affected.
Iagree not to restrict the use of any data or results that arise
from this study provided such a use is only for scientific
purpose(s).
I have been given an information sheet giving details of the
study.
I fully consent to participate in the above study.
Signature
ASSOCIATION OF MATRIX METALLO PROTEINASE-2
GENE PROMOTER POLYMORPHISM WITH
MYOCARDIAL INFARCTION
PROFORMA
Name: Age/Sex: IP /OP No:
Address: Phone No:
Ward
Diagnosis:
Presenting complaints: Duration:
Past history:
Chest pain
Hypertension
Diabetes
No.
Personal History:
Smoking
Alcoholism
Tobacco chewing
Menstrual history
Diet history
Family history
Examination :
Vital data :
Heart Rate :
Blood pressure (mean) :
Height :
Weight :
Systemicexamination :
CVS
RS
ABDOMEN
CNS
Impression
Investigations:
Fasting lipid profile
Plasma MMP-2 estimation by ELISA
Genotyping by polymerase chain reaction and restriction fragment length
polymorphism.
Coronary Angiography
ECG.
SIMILARITY CHECK 17% SIMILARITY

